CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Immunomodulation
Melanoma
Oncolytic Virotherapy
T-Lymphocytes
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
04
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
15
4
2022
Statut:
ppublish
Résumé
Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibitors (ICI). Using a BRAF Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. Immune characterization showed HSV or dual therapy led to fewer intratumoral Treg, although with a more activated phenotype, together with more effector CD8 +T cells. Tocky analysis further showed that HSV/BRAFi dual treatment reduced the Tocky signal (reflecting engagement with cognate antigen), in both Treg and conventional subsets of CD4+, but not in CD8 +cells. However, a higher percentage of Treg than of conventional CD4 +maintained frequent engagement with antigens on treatment, reflecting a predominance of suppressive over effector function within the CD4 +compartment. The only T cell subset which correlated with a reduction in tumor growth was within Tocky signal positive conventional CD4+, supporting their therapeutic role. Targeting CD25 high, antigen-engaged Treg with a depleting anti-CD25 ICI, achieved complete cures in 100% of mice with triple therapy. Transcriptomic analysis confirmed reduction in Foxp3 on addition of anti-CD25 to HSV/BRAFi, as well as increases in expression of genes reflecting interferon signaling and cytotoxic activity. Combination HSV/BRAFi is an immunogenic therapy for BRAF mutant melanoma, but cannot fully control tumors. Dual therapy results in changes in T cell dynamics within tumors, with relatively maintained antigen signaling in Treg compared with conv CD4+. Antigen-engaged CD4 +effectors correlate with tumor growth control, and depletion of Treg by addition of an anti-CD25 ICI, releasing suppression of conventional CD4 +effectors by Treg, enhances survival and activates immune signaling within tumors.
Sections du résumé
BACKGROUND
Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibitors (ICI).
METHODS
Using a BRAF
RESULTS
Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. Immune characterization showed HSV or dual therapy led to fewer intratumoral Treg, although with a more activated phenotype, together with more effector CD8 +T cells. Tocky analysis further showed that HSV/BRAFi dual treatment reduced the Tocky signal (reflecting engagement with cognate antigen), in both Treg and conventional subsets of CD4+, but not in CD8 +cells. However, a higher percentage of Treg than of conventional CD4 +maintained frequent engagement with antigens on treatment, reflecting a predominance of suppressive over effector function within the CD4 +compartment. The only T cell subset which correlated with a reduction in tumor growth was within Tocky signal positive conventional CD4+, supporting their therapeutic role. Targeting CD25 high, antigen-engaged Treg with a depleting anti-CD25 ICI, achieved complete cures in 100% of mice with triple therapy. Transcriptomic analysis confirmed reduction in Foxp3 on addition of anti-CD25 to HSV/BRAFi, as well as increases in expression of genes reflecting interferon signaling and cytotoxic activity.
CONCLUSIONS
Combination HSV/BRAFi is an immunogenic therapy for BRAF mutant melanoma, but cannot fully control tumors. Dual therapy results in changes in T cell dynamics within tumors, with relatively maintained antigen signaling in Treg compared with conv CD4+. Antigen-engaged CD4 +effectors correlate with tumor growth control, and depletion of Treg by addition of an anti-CD25 ICI, releasing suppression of conventional CD4 +effectors by Treg, enhances survival and activates immune signaling within tumors.
Identifiants
pubmed: 35338089
pii: jitc-2021-004410
doi: 10.1136/jitc-2021-004410
pmc: PMC8961178
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
EMBO J. 2018 Aug 15;37(16):
pubmed: 29991564
Mol Ther. 2015 May;23(5):931-942
pubmed: 25619724
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Immunity. 2017 Apr 18;46(4):577-586
pubmed: 28410988
Nat Commun. 2020 Dec 7;11(1):6262
pubmed: 33288749
J Virol. 2005 Aug;79(15):9970-81
pubmed: 16014957
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32759235
Immunology. 2020 May;160(1):24-37
pubmed: 32022254
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
Sci Transl Med. 2018 Dec 12;10(471):
pubmed: 30541787
Eur J Cancer. 2017 Sep;83:247-257
pubmed: 28756137
Cancer Gene Ther. 2014 Jul;21(7):283-9
pubmed: 24924199
Lancet. 2020 Jun 13;395(10240):1835-1844
pubmed: 32534646
Pediatr Blood Cancer. 2006 Jun;46(7):745-54
pubmed: 16124003
J Cell Biol. 2018 Aug 6;217(8):2931-2950
pubmed: 29941474
Oncoimmunology. 2016 Oct 14;5(12):e1238557
pubmed: 28123875
Cancer Cell. 2009 Apr 7;15(4):294-303
pubmed: 19345328
Nat Immunol. 2007 Dec;8(12):1353-62
pubmed: 17982458
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Nat Immunol. 2016 Nov;17(11):1322-1333
pubmed: 27595233
Immunol Rev. 2007 Dec;220:199-213
pubmed: 17979848